LIPOSYN II INJ 10% 700 MG / 100 ML
EGG PHOSPHOLIPIDS : 700 MG / 100 ML SAFFLOWER OIL : 5.0 G / 100 ML SOYBEAN OIL : 5.0 G / 100 ML · DIN 00818712 · HOSPIRA HEALTHCARE ULC
Health Canada status: CANCELLED POST MARKET
What is LIPOSYN II INJ 10%?
LIPOSYN II INJ 10% 700 MG / 100 ML contains EGG PHOSPHOLIPIDS : 700 MG / 100 ML SAFFLOWER OIL : 5.0 G / 100 ML SOYBEAN OIL : 5.0 G / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 00818712, held by HOSPIRA HEALTHCARE ULC, supplied as EMULSION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 01-Aug-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LIPOSYN II INJ 10% used for?
LIPOSYN® II Injection (Intravenous Fat Emulsion 10% and 20%) is indicated as a source of calories for patients requiring parenteral nutrition. This includes pre- and post-operative nutritional disorders and nutritive disorders resulting from decreased or inhibited intestinal absorption, as with tumours of the digestive tract, or in ulcerative colitis and terminal ileitis. LIPOSYN® II Injection is also indicated in burn cases, where nitrogen loss can be excessive, in prolonged states of unconsciousness if tube feeding is inadvisable and in cachexia due to serious diseases other than of the alimentary tract. Where such nutrition is required for extended periods of time (more than five days), LIPOSYN® II Injection is also indicated as a source of essential fatty acids to prevent or reverse biochemical changes in fatty acid composition of plasma lipids (elevated triene/tetraene ratio) and the clinical manifestations of EFAD.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00818712 |
|---|---|
| Brand name | LIPOSYN II INJ 10% |
| Generic / active ingredient | EGG PHOSPHOLIPIDS : 700 MG / 100 ML SAFFLOWER OIL : 5.0 G / 100 ML SOYBEAN OIL : 5.0 G / 100 ML |
| Manufacturer | HOSPIRA HEALTHCARE ULC |
| Strength | 700 MG / 100 ML |
| Dosage form | EMULSION |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B05BA02 FAT EMULSIONS |
| AHFS class | 40:20.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 01-Aug-2014 |
| Original market date | 1992-01-01 00:00:00 |
How is it stored and handled?
Store at controlled temperature below 25 °C. Do not freeze.
How is it supplied?
LIPOSYN® II 10% Injection is supplied in 100 mL, 200 mL and 500 mL single-dose containers and in 25 mL and 50 mL Syringe Pump Units. LIPOSYN® II 20% Injection is supplied in 200 mL and 500 mL single-dose containers, and in 25 mL and 50 mL Syringe Pump Units.
What can be used instead?
Other Canadian products sharing ATC code B05BA02 FAT EMULSIONS. 3 of 13 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CLINOLEIC 20% | 16 % | EMULSION | BAXTER CORPORATION | MARKETED | DIN 02344327 |
| INTRALIPID 20% | 20 % | EMULSION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02065673 |
| SMOFLIPID 20% | 6 % | EMULSION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02396963 |
| 10% TRAVAMULSION LIQ IV | 1.2 G / 100 ML | LIQUID | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | CANCELLED POST MARKET | DIN 02016028 |
| 20% TRAVAMULSION LIQ IV | 20 G / 100 ML | LIQUID | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | CANCELLED POST MARKET | DIN 02016036 |
| COLIP 20% | 15 G / 100 ML | EMULSION | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | CANCELLED POST MARKET | DIN 02230772 |
| INTRALIPID 10% | 10 % | EMULSION | FRESENIUS KABI CANADA LTD | DORMANT | DIN 02065681 |
| INTRALIPID 30% | 30 % | EMULSION | FRESENIUS KABI CANADA LTD | DORMANT | DIN 02216175 |
| LIPOSYN II 10% | 5 % | EMULSION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 00720976 |
| LIPOSYN II 20% | 10 % | EMULSION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 00720968 |
Who else supplies FAT EMULSIONS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. FAT EMULSIONS appears in 16 registered pack listings across 3 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.